CTRI/2014/07/004768已完成4 期
A prospective, open-label, multicenter, randomized, active-controlled study to compare the efficacy of Alpecin Liquid Anti Hair Loss Treatment to Minoxidil 5% solution in the management of androgenetic alopecia
Fullife Healthcare Pvt Ltd0 个研究点目标入组 210 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1.Males aged between 18-55 years
- •2.Balding stage of III-V on the Hamilton scale and use of global photography to confirm the Hamilton-Norwood stage of balding
- •3.At least 20% telogen ratio in trichogram
- •4.Willingness to participate and signing the informed consent form
排除标准
- •1.Diagnosed with pathologic forms of alopecia like alopecia areata, trichotillomania, scarring alopecia, drug based alopecia
- •2.Diagnosed with dermatologic conditions like eczema, fungal scalp infections, seborrheic dermatitis, recurrent herpes, pityriasis versicolor, psoriasis, pigmentary disorders (vitiligo, chloasma), chronic lupus erythematous
- •3.History of chemotherapy
- •4.Known hypersensitivity to Mx-5 or any excipients of Alpecin that could interfere directly/indirectly with the study
- •5.Use of any anti-hair loss treatment within the last 6 months prior to the screening visit
- •6.Participation in another trial of an investigational product within 28 days prior to the screening visit
- •7.Any other clinically significant medical condition e.g. active infections, cardiac, psychiatric, neurological, pulmonary, immunological conditions, or hypertension etc. which may, in the judgment of the investigator, interfere with the subjectâ??s ability to participate in the study.
研究者
相似试验
进行中（未招募）
1 期
A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (everolimus) and AxiTinib in metastatic kidney cancer (BERAT study)metastatic renal cell carcinoma (mRCC)MedDRA version: 18.0Level: LLTClassification code 10050076Term: Metastatic renal carcinomaSystem Organ Class: 100000004864EUCTR2011-005939-78-DECESAR Central European Society for Anticancer Drug Research-EWIV
尚未招募
4 期
MeRethon RCTCTRI/2021/08/035665Meril Life Sciences Pvt Ltd
进行中（未招募）
1 期
A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimensMedDRA version: 19.1Level: LLTClassification code 10009310Term: CLLSystem Organ Class: 100000004864Chronic Lymphocytic LeukemiaEUCTR2015-004985-27-NLHOVON Foundation
招募中
2 期
A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of Gazyvaro (obinutuzumab) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens. (GIVE trial)10024324Chronic Lymphocytic LeukemiaCLLNL-OMON54803HOVO70
进行中（未招募）
1 期
Study to evaluate 3 type of treatment (masitinib + FOLFIRI, or masitinib alone, or FOLFIRI alone) in the treatment of patients with metastatic colorectal cancer that have received 2 or 3 previous therapiesMetastatic colorectal cancer after 2 or 3 previous lines of treatmentMedDRA version: 17.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2013-000493-30-ESAB Science75